Halberd Corporation Appoints Anthony Mirabelli Vice-President, Mergers & Acquisitions

JACKSON CENTER, PA / ACCESSWIRE / September 8, 2021 / Halberd Corporation (OTC PINK:HALB) announced the appointment of Anthony Mirabelli to the position of Vice-President, Mergers & Acquisitions. Mirabelli will be responsible for negotiating joint ventures, license agreements and other activities whereby Halberd can capitalize on his vast experience in pharmaceutical and medical device development and sales.

Anthony Mirabelli’s extensive experience includes Director at Tessera, LLC, an Xperi Corporation, and COO of InFerGene, and has over thirty years of experience in bio-pharmaceuticals research & bio-pharmacodynamics, product development, sales, marketing and operations management, involved with full profit & loss (P & L) responsibility, project management, overall plant operations, facility and production planning, process improvement, site and facility assessment, cost reduction, and regulatory affairs. He is a founding member of the Institute of Food Technology Biotech Committee; Member of the Board of Directors of the Enzyme Technical Association, and served as the Sub-Committee Chairman for its Food Chemical Codex Revision Committee. He is also a member of the Clinical Chemist Association. Mirabelli did his undergraduate work at Clemson University with graduate work in biophysics-engineering at LIU & SUNY Stony Brook School of Basic Health Sciences & Medicine.

Anthony Mirabelli indicated, “I am excited to be joining the Halberd team, as the corporation is on the precipice of an amazing breakthrough with its Antigen/Antibody diagnostics and therapeutic technologies.”

William A. Hartman, Halberd Corporation’s Chairman, President & CEO, stated, “We are pleased that someone of Anthony’s accomplishments and extensive experience in various aspects of the Health Care Industry has agreed to join Halberd’s growing team of experts. Anthony’s appointment at this time is strategically very important, because Halberd Corporation’s R&D in developing successful treatments for PTSD and Alzheimer’s Disease has shown great promise, and we are in a position where we will need his services shortly to help us negotiate organizational relationships with other companies and possibly government agencies.

To get the latest news on Halberd’s exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.

For more information please contact:
William A. Hartman

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies.

Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and an allowed but not yet issued patent for the treatment of Cockayne Syndrome.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis. The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment, or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.”

SOURCE: Halberd Corporation

View source version on accesswire.com:

error: Content is protected !!